Fig. 7
Formo inhibits in vivo tumor growth. a and b, Formo suppresses the in vivo tumor development of HCC827 cells. The tumor volume (a) and tumor weight (b) of HCC827-derived xenograft tumors treated with vehicle control, Formo, or Osi. C and D, Formo suppresses the in vivo tumor development of H3255 cells. The tumor volume (c) and tumor weight (d) of H3255-derived xenograft tumors treated with vehicle control, Formo, or Osi. E and F, Formo suppresses the in vivo tumor development of H1975 cells. The tumor volume (e) and tumor weight (f) of H1975-derived xenograft tumors treated with vehicle control, Formo, or Osi. G and H, Formo suppresses the in vivo tumor development of A549 cells. The tumor volume (g) and tumor weight (h) of A549-derived xenograft tumors treated with vehicle control, Formo, or Osi. i, Immunohistochemistry staining analysis of Ki67, p-EGFR, p-Akt, and Mcl-1 in HCC827-derived xenograft tumors. j, The qualification analysis of IHC staining of Ki67, p-EGFR, p-Akt, and Mcl-1. k, IB analysis of the expression of p-EGFR, p-Akt, and Mcl-1 in HCC827-derived xenograft tumors with vehicle control, Formo, or Osi treatment. *p < 0.05, **p < 0.01, ***p < 0.001. ns, not statistically significant. Scale bar, 25 μm